{"classes":[{"categories":[{"measurements":[{"comment":"SD is not available because only 1 participant had the duration of IRR recorded and the SD for one value is not defined.","groupId":"OG000","spread":"NA","value":"165.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"The duration, in minutes, of IRRs during all cycles, where obinutuzumab was administered as an SDI.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"The safety population (113 participants) included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"All cycles including maintenance (1 cycle: 21 or 28 days depending on the chemotherapy selected; up to approximately 2.5 years)","title":"Duration of Grade >=3 IRRs Associated With the Obinutuzumab Administered as an SDI by Cycle","type":"SECONDARY","unitOfMeasure":"Minutes"}